NCT02925000: A trial that was reported late by Taiwan Liposome Company
This trial has reported, although it was 244 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02925000 |
|---|---|
| Title | A Phase I/IIa, Open Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 19, 2017 |
| Completion date | Oct. 6, 2020 |
| Required reporting date | Oct. 6, 2021, midnight |
| Actual reporting date | June 7, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 244 |